Craft

Kuros Biosciences

Stock Price

CHF5.9

2024-02-16

Market Capitalization

CHF217.7 M

2024-02-16

Revenue

CHF18 M

FY, 2022

Kuros Biosciences Summary

Company Summary

Overview
Kuros Biosciences is a biopharmaceutical company that engages in the development of biopharmaceutical products for tissue repair and bone regeneration. It offers orthobiologics pipeline products including magnetos granules and magnetos putty, for the treatment of orthopedics, spinal, and dental problems, neuroseal, synthetic tissue sealant for the prevention of cerebrospinal fluid leakage, fibrin-PTH, for the treatment of tibial plateau fractures, etc.
Type
Public
Status
Active
Founded
2000
HQ
Zürich, CH | view all locations
Website
https://kurosbio.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Michael Grau

    Michael Grau, Chief Financial Officer

  • Joost De Bruijn

    Joost De Bruijn, Chief Executive Officer, Director

  • Alistair Irvine

    Alistair Irvine, Chief Business Officer

  • Philippe Saudan

    Philippe Saudan, Chief Development Officer

Operating MetricsView all

Spinal Fusion Surgeries

10K
100.0%

FY, 2022

LocationsView all

3 locations detected

  • Zürich, ZH HQ

    Switzerland

    Wagistrasse 25

  • Boston, MA

    United States

    22 Boston Wharf Rd

  • Bilthoven, UT

    Netherlands

    Prof. Bronkhorstlaan 10 Building 48

Kuros Biosciences Financials

Summary Financials

Revenue (H1, 2023)
CHF12.9M
Gross profit (H1, 2023)
CHF12.4M
Net income (H1, 2023)
(CHF5.1M)
Cash (H1, 2023)
CHF16.9M
EBIT (H1, 2023)
(CHF4.5M)
Enterprise value
$209.3M

Footer menu